HRP20181939T4 - Postupci za liječenje osteogenesis imperfecta - Google Patents
Postupci za liječenje osteogenesis imperfecta Download PDFInfo
- Publication number
- HRP20181939T4 HRP20181939T4 HRP20181939TT HRP20181939T HRP20181939T4 HR P20181939 T4 HRP20181939 T4 HR P20181939T4 HR P20181939T T HRP20181939T T HR P20181939TT HR P20181939 T HRP20181939 T HR P20181939T HR P20181939 T4 HRP20181939 T4 HR P20181939T4
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- use according
- seq
- Prior art date
Links
- 206010031243 Osteogenesis imperfecta Diseases 0.000 title claims 4
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 210000000988 bone and bone Anatomy 0.000 claims 6
- 230000002485 urinary effect Effects 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 2
- 102000012422 Collagen Type I Human genes 0.000 claims 2
- 108010022452 Collagen Type I Proteins 0.000 claims 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 claims 2
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 claims 2
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 claims 2
- 102000004264 Osteopontin Human genes 0.000 claims 2
- 108010081689 Osteopontin Proteins 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 230000010256 bone deposition Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 229940096422 collagen type i Drugs 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims 1
- 102000013563 Acid Phosphatase Human genes 0.000 claims 1
- 108010051457 Acid Phosphatase Proteins 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108010050808 Procollagen Proteins 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Protutijelo ili njegov ulomak koji veže antigen koji se specifično veže na i neutralizira ljudski TGFβ1, TGFβ2, i TGFβ3 za uporabu za liječenje osteogenesis imperfecta (OI) kod subjekta kojem je to potrebno naznačeno time što protutijelo ili njegov ulomak koji veže antigen obuhvaća varijabilnu regiju teškog lanca koja sadrži tri regije koje određuju komplementarnost (CDR) koje sadrže aminokiselinske sekvence SEQ ID NOs: 4, 5, i 6; i varijabilnu regiju lakog lanca koja sadrži tri CDR koje sadrže aminokiselinske sekvence SEQ ID NOs: 7, 8, i 9.
2. Protutijelo ili njegov ulomak koji veže antigen za upotrebu prema zahtjevu 1, naznačeno time što antitijelo ili njegov ulomak koji veže antigen sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 10 i varijabilnu regiju lakog lanca koja sadrži aminokiselinska sekvencu SEQ ID NO: 11.
3. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 1 ili 2, naznačeno time što protutijelo ili njegov ulomak koji veže antigen dalje sadrži ljudsku IgG4 konstantnu regiju.
4. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 3, naznačeno time što ljudska IgG4 konstantna regija sadrži aminokiselinsku sekvencu iz SEQ ID NO: 12.
5. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži ljudsku κ konstantnu regiju lakog lanca.
6. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 5, naznačeno time što ljudska κ konstantna regija lakog lanca sadrži aminokiselinsku sekvencu iz SEQ ID NO: 13.
7. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od zahtjeva 1 ili zahtjeva 2, naznačeno time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži ljudsku IgG4 konstantnu regiju, i ljudsku κ konstantnu regiju lakog lanca.
8. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 7, naznačeno time što ljudska IgG4 konstantna regija sadrži aminokiselinsku sekvencu iz SEQ ID NO: 12, i ljudska κ konstantna regija lakog lanca sadrži aminokiselinsku sekvencu iz SEQ ID NO: 13.
9. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo sadrži teški lanac koji sadrži aminokiselinsku sekvencu iz SEQ ID NO: 14.
10. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo sadrži lagani lanac koji sadrži aminokiselinsku sekvencu iz SEQ ID NO: 15.
11. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo sadrži teški lanac koji sadrži aminokiselinsku sekvencu iz SEQ ID NO: 14, i lagani lanac koji sadrži aminokiselinsku sekvencu iz SEQ ID NO: 15.
12. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen poboljšava koštani parametar odabran iz skupine koja sadrži gustoću volumena kosti (BV/TV), ukupnu površinu kosti (BS), gustoću površine kosti (BS/BV), broj trabekula (Tb.N), trabekularnu debljinu (Tb.Th), trabekularno razdvajanje (Tb.Sp), i ukupni volumen (Dens TV).
13. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen inhibira razgradnju kosti.
14. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen smanjuje biomarker seruma resorpcije kosti odabran iz skupine koju čine urinarni hidroksiprolin, urinarni ukupni piridinolin (PYD), urinarni slobodni deoksipiridinolin (DPD), urinarni N-terminalni križni telopeptid kolagena tip-I (NTX), urinarni ili serumski C-terminalni križni telopeptid kolagena tip-I (CTX), koštani sijaloprotein (BSP), osteopontin (OPN), i kisela fosfataza otporna na tartarat 5b (TRAP).
15. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen povećava biomarker seruma odlaganja kosti odabran iz skupine koju čine ukupna alkalna fosfataza, alkalna fosfataza specifična za kosti, osteokalcin, i prokolagen tip-I (C-terminalni/N-terminalni).
16. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen potiče odlaganje kostiju.
17. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačeno time što protutijelo ili njegov ulomak koji veže antigen poboljšava funkciju ne-skeletnog organa koji je pogođen s OI odabranim iz skupine koja se sastoji od funkcije sluha, funkcije pluća, i funkcije bubrega.
18. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 1, naznačeno time što se navedeno protutijelo ili njegov ulomak koji veže antigen koristi u kombinaciji s barem jednim terapeutskim sredstvom.
19. Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 18, naznačeno time što je barem jedno terapeutsko sredstvo je odabrano iz skupine koju čine bisfosfonat, paratiroidni hormonski analog koji potiče stvaranje kostiju, kalcitonin, i selektivni modulator receptora estrogena (SERM).
20. Protutijelo ili ulomak koji veže antigen za uporabu prema zahtjevu 18 ili 19, naznačeno time što je barem jedno terapeutsko sredstvo paratiroidni hormonski analog koji potiče stvaranje kostiju.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803647P | 2013-03-20 | 2013-03-20 | |
| US201361875399P | 2013-09-09 | 2013-09-09 | |
| US201361883151P | 2013-09-26 | 2013-09-26 | |
| EP14717386.8A EP2976359B2 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
| PCT/US2014/031279 WO2014153435A1 (en) | 2013-03-20 | 2014-03-20 | Methods for treating osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20181939T1 HRP20181939T1 (hr) | 2019-01-25 |
| HRP20181939T4 true HRP20181939T4 (hr) | 2022-05-13 |
Family
ID=50483613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181939TT HRP20181939T4 (hr) | 2013-03-20 | 2014-03-20 | Postupci za liječenje osteogenesis imperfecta |
| HRP20192277TT HRP20192277T1 (hr) | 2013-03-20 | 2019-12-17 | Postupci za liječenje osteogenesis imperfecta |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192277TT HRP20192277T1 (hr) | 2013-03-20 | 2019-12-17 | Postupci za liječenje osteogenesis imperfecta |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9598486B2 (hr) |
| EP (3) | EP2976359B2 (hr) |
| JP (3) | JP6483086B2 (hr) |
| KR (1) | KR102257138B1 (hr) |
| CN (2) | CN111000997A (hr) |
| AU (1) | AU2014235933B2 (hr) |
| CA (1) | CA2907422C (hr) |
| CL (1) | CL2015002801A1 (hr) |
| DK (2) | DK3312195T3 (hr) |
| EA (1) | EA032327B1 (hr) |
| ES (2) | ES2763869T3 (hr) |
| HK (2) | HK1213576A1 (hr) |
| HR (2) | HRP20181939T4 (hr) |
| HU (1) | HUE046702T2 (hr) |
| IL (2) | IL241461B (hr) |
| LT (2) | LT2976359T (hr) |
| MX (2) | MX369360B (hr) |
| MY (1) | MY172324A (hr) |
| PH (2) | PH12015501864A1 (hr) |
| PL (2) | PL3312195T3 (hr) |
| PT (2) | PT3312195T (hr) |
| RS (2) | RS58188B2 (hr) |
| SG (2) | SG10201701985YA (hr) |
| SI (2) | SI2976359T2 (hr) |
| TW (1) | TWI629995B (hr) |
| UY (1) | UY35493A (hr) |
| WO (1) | WO2014153435A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3312195T (pt) * | 2013-03-20 | 2019-12-23 | Baylor College Medicine | Métodos de tratamento de osteogénese imperfeita |
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| CN106755395B (zh) * | 2016-12-16 | 2020-05-12 | 山东第一医科大学(山东省医学科学院) | Xi型成骨不全致病基因fkbp10的突变位点及其应用 |
| AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
| EP3571227A1 (en) * | 2017-01-20 | 2019-11-27 | Sanofi | Anti-tgf-beta antibodies and their use |
| TWI787230B (zh) * | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI788321B (zh) * | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
| US20190248881A1 (en) * | 2017-12-04 | 2019-08-15 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| AU2019301283A1 (en) | 2018-07-10 | 2021-02-04 | Sanofi | Combination therapies against cancer targeting CD38 and TGF-beta |
| KR20230112629A (ko) * | 2020-10-23 | 2023-07-27 | 에이치큐 한 | 종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도 |
| EP4334347A1 (en) * | 2021-05-07 | 2024-03-13 | Baylor College of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| WO2023077131A1 (en) * | 2021-11-01 | 2023-05-04 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6716836A (hr) * | 1967-12-11 | 1969-06-13 | ||
| US7368111B2 (en) * | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2000028982A2 (en) * | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| CA2352532C (en) * | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| DK1850873T3 (en) * | 2005-02-08 | 2019-03-18 | Genzyme Corp | ANTIBODIES AGAINST TGF-BETA |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CA2632799A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
| TWI667038B (zh) * | 2007-02-09 | 2019-08-01 | 美商艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| JP2010528586A (ja) * | 2007-04-26 | 2010-08-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| EA201001162A1 (ru) * | 2008-01-15 | 2010-12-30 | Калобиос Фармасьютикалс, Инк. | Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf |
| EP2421559B1 (en) * | 2009-04-24 | 2016-07-20 | Vanderbilt University | Anti-tgf-beta induction of bone growth |
| PT3312195T (pt) * | 2013-03-20 | 2019-12-23 | Baylor College Medicine | Métodos de tratamento de osteogénese imperfeita |
-
2014
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en active Pending
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active IP Right Grant
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en active Application Filing
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
-
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864A1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
- 2015-09-18 MX MX2019009122A patent/MX2019009122A/es unknown
-
2016
- 2016-02-11 HK HK16101478.1A patent/HK1213576A1/zh unknown
- 2016-02-11 HK HK18112865.7A patent/HK1253717A1/zh unknown
-
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
-
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261A1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
-
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
-
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US20220195025A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181939T4 (hr) | Postupci za liječenje osteogenesis imperfecta | |
| JP2016519093A5 (hr) | ||
| HRP20201733T1 (hr) | Postupci liječenja stanja povezanih s aktivacijom komplementa ovisnim o masp-2 | |
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| PH12020550408A1 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
| HRP20151210T1 (hr) | Postupak za lijeäśenje multiple skleroze inhibicijom aktivnosti il-17 | |
| RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
| RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| JP2021502984A5 (hr) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2009240323A5 (hr) | ||
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| HRP20211935T1 (hr) | Protutijela anti-alfa-sinuklein i njihove uporabe | |
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| JP2015504421A5 (hr) | ||
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| NZ611387A (en) | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment | |
| PE20110801A1 (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f | |
| RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
| JP2009523421A5 (hr) | ||
| RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| HRP20230065T1 (hr) | Humanizirana protutijela koja prepoznaju alfa-sinuklein | |
| UA104587C2 (ru) | Моноклональное антитело и способ его применения |